underlying disease. All study protocols were performed under the permission of the Ethics Committee of Kitasato University and written informed consent was obtained before study entry.
Analysis of Fibrillation Waves
Spectral analyses used data from the surface ECG lead V1, which were digitally stored on-line on a microcomputer at sampling rate of 1 kHz, and the QRS-T complexes were subtracted using a template matching algorithm. 15 Frequency analysis were performed off-line on a microcomputer (BIMUTUS II, Kissei Comtec Co Ltd, Matsumoto, Japan). Frequency analysis of the subtracted ECG involved 3 steps: (1) bandpass filtering, (2) application of a Hamming window and (3) 4096-point fast Fourier transformation. A 50% overlap of adjacent spectral analyses allowed the use of an average of 20 epochs of analyses within a single 44-s data set. 15 After spectral analysis, recordings were displayed as power spectra (Fig 1) , which were quantified by measuring the peak frequency signal with the maximum magnitude derived from each epoch. The peak frequency of the spectrum in the 3-12 Hz range was converted to a cycle length (CL in ms =1,000 /frequency), defined as the fibrillation CL (FCL), averaged from 20 epochs. Temporal variability was expressed as the FCL coefficient of variation (FCL-CV) of 20 consecutive epochs. As the index for the change in FCL during the follow-up period, ∆FCL was calculated by subtracting the baseline FCL from the FCL after the follow-up period, and it was corrected by dividing by the follow-up period because each patient in the present study had a different follow-up period.
Statistical Analysis
All data are expressed as mean ± SD. A paired t-test was used for comparison between 2 groups and results were considered significant at p<0.05.
Results
The mean age of the patients enrolled in this study was 67±9 years old, and the female:male ratio was 11:27. Underlying heart diseases were ischemic heart disease (4), cardiomyopathy (3), valvular heart disease (3), and other (1) . None of the remaining 26 patients had structural heart disease. The duration of AF at the time of study entry was 73±62 months (range 3-201, median 76 months). The mean left atrial dimension was 50±9 mm (range 37-78) and the mean ejection fraction was 60±11% (range 40-77). None of the patients suffered cardiac events during the mean follow-up period of 5±3 (1-14) months. Relationship between corrected fibrillation cycle length (∆FCL) and the other parameters. There was a significant negative correlation with baseline FCL (p=0.003), and a tendency towards a negative correlation with left atrial dimension (LAD), but it was not significant. After follow-up, the FCL had significantly shortened from 160±20 ms to 151±19 ms (p=0.01) and the FCL-CV had also decreased from 15±9% to 12±5% (p=0.03).
Corrected ∆FCL was -2.4±7.6 ms/month (range -25.8 to +16.0). As shown in Fig 3, there was no correlation between AF duration and the 3 fibrillation wave parameters (baseline FCL, baseline FCL-CV and corrected ∆FCL), although corrected ∆FCL showed a significant negative correlation with the baseline FCL ( Fig 4A) , but no correlation with left atrial dimension ( Fig 4B) .
Although the mean FCL was shortened overall in the present study, some cases showed prolongation during the follow-up period. Table 1 compares patients with negative ∆FCL (n=25) and positive ∆FCL (n=13). There was no significant difference between the 2 groups in sex, age, existence of heart disease, AF duration, left atrial dimension and LV ejection fraction. There were significant difference in baseline FCL (165±21 ms vs 152±13 ms, p=0.049) and baseline FCL-CV(18±9% vs 10±5%, p=0.003).
Discussion
The present evaluation of the FCL of relatively longlasting PAF by frequency analysis revealed several interesting findings. First, mean FCL and FCL-CV decreased overall during a follow-up period of 1-14 months. Second, there was no correlation between AF duration and the baseline FCL, but the corrected ∆FCL, the index of change in FCL, showed a significant correlation with baseline FCL. Third, patients with negative ∆FCL showed longer FCL and larger FCL-CV at baseline than those with positive ∆FCL.
AF Duration and FCL Shortening
The results from experimental studies concerning electrical remodeling indicate that atrial refractoriness shortens over time in patients with AF, and clinical studies have documented that AF patients have shorter atrial refractoriness than controls. 20 However, because this shortening of atrial refractoriness appears to be time dependent, the longer the AF lasts, the shorter the atrial refractoriness should be and to clarify this assumption, atrial refractoriness has to be evaluated repeatedly, preferably non-invasively.
Clinically, it is considered that paroxysmal AF eventually develops into its chronic form. 21 Bollman et al analyzed atrial fibrillation waves in the surface ECG in patients with paroxysmal (duration 1-665 min) and persistent (duration 3-24 months) AF and showed that the fibrillatory frequency of PAF was higher than that of paroxysmal AF (6.9±0.5 Hz vs 5.1±0.7 Hz, p<0.001). 17 Fujiki et al also used a similar system and reported that patients with PAF (>3 days) had a shorter FCL of 139±16 ms than those with paroxysmal AF (178±26 ms, p<0.001). 18 In the present study, we found that FCL and FCL-CV still decreased in at least some patients with relatively long-lasting PAF, and this is the first report documenting long-term changes in fibrillation wave properties in the same patients over time.
Interestingly, AF duration did not correlate with baseline FCL at the time of study entry, although it showed significant shortening at the end of the follow-up period. There are 3 possible explanations. First, because the patients in the present study had relatively long-lasting AF, the shortening of the FCL might have been close to the nadir, so that the AF duration might not have had as strong an influence on FCL shortening as in patients with shorter duration AF. Second, because the measurement of FCL using surface ECG is strongly dependent on the recording of fibrillation waves, it could be influenced by other factors, such as body size, obesity, etc. However, because we compared data obtained from the same patients in the present study, these additional factors could be excluded and even small changes in FCL were documented in these patients. Third, cardio-active medications, such as digitalis or -blockade, might affect the FCL, especially in the baseline evaluation. Although patients taking antiarrhythmic agents were excluded, the basic medications allowed in the present study might affect atrial refractoriness through their action on the autonomic nervous system.
Baseline FCL as a Predictor of FCL Shortening
We found a negative correlation between corrected ∆FCL and baseline FCL, which indicates that a larger decrease in FCL (larger negative ∆FCL) is expected in patients with longer baseline FCL and bigger temporal variation of FCL. Because shortening of FCL was not always observed, our study population may include some patients with heterogeneous electrophysiological properties. Additionally, because the baseline FCL and FCL-CV were the only factors that differed between the negative and positive ∆FCL patients, the change in FCL might be reflecting only a natural fluctuation in at least some cases. However, because the mean FCL was significantly shortened overall, it is possible to say that a population of patients with relatively long-lasting AF includes some who can show additional shortening of FCL (ie, progression of atrial electrical remodeling).
Our finding also seems to indicate the existence of a nadir of atrial refractoriness shortening as a result of atrial electrical remodeling. Although we observed that FCL still decreased in patients with relatively long-lasting PAF, the FCL could not be shortened when it was very close to the nadir. The time to reach this point was unclear in the present study, but there seems to be individual variation because there was no significant relationship between corrected ∆FCL and AF duration.
Usefulness of Spectral Analysis of Fibrillation Waves in the Surface ECG
We used spectral analysis of fibrillation waves in the surface ECG, which has have some benefits in comparison with the classical manual analysis of fibrillation waves, because the fibrillation waves in the surface ECG trace include very small deflections that manual or visual detection may include as human detection errors. In contrast, because spectral analysis of the digital ECG recording does not include human sampling error, it is a purely objective analysis of the fibrillation waves. Additionally, because the QRS-T waves are digitally subtracted from the original ECG traces, the result of the spectral analysis becomes more sensitive, especially for low-frequency data. However, to apply this intelligent method, the ECG traces must be recorded in a specific recorder, so ECG recordings made in other machines or previous print-based ECG traces cannot be used.
Study Limitations
First, although the study reached some conclusions, the results were from a relatively small number of patients. Second, subjects in this study included patients with organic heart disease and changes in their basic disease may have influenced the results. Third, the AF duration data were mainly obtained from the patient's history and ECG recording during a limited time, so asymptomatic AF or unknown conversion cannot be excluded. Fourth, temporal fluctuations of the FCL (eg, daily variation, influence of changes accompanying the underlying diseases and errors of measurement) can not be absolutely excluded.
Clinical Implications
This is the first report to document progressive shortening of the FCL in relatively long-lasting PAF, and the usefulness of spectral analysis for repeat evaluation of the fibrillation waves on ECG in the same patient. Our method can be used to monitor atrial refractoriness in patients with PAF, especially over the long term, and could assist in antiarrhythmic drug selection because of its focus on electrical remodeling.
